Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "SEC"

2487 News Found

Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr
News | May 26, 2025

Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr

The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25


CPHI & PMEC China sees surge in international attendance
News | May 24, 2025

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth


Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025
News | May 23, 2025

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025


Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio
News | May 21, 2025

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion


Venus Remedies joins United Nations Global Compact
Sustainability | May 21, 2025

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery


IICP and Indegene partner to enable more inclusive society
News | May 20, 2025

IICP and Indegene partner to enable more inclusive society

IICP is a registered charitable society working in the disability sector since 1974


JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
News | May 16, 2025

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25


Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
News | May 14, 2025

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.


Briefs: Zydus and CuraTeQ Biologics
Drug Approval | May 14, 2025

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA